UCLA Study Points to Need for Informed Decision-Making in Prostate Cancer
The study evaluated SEER data of over 37,000 prostate cancer patients and found an overwhelming majority of patients (58%) received radiation treatment regardless of overall disease prognosis. The lead study author hopes these findings enlighten the public and allow physicians to make an informed decision when it comes to the best treatment option for men who may or may not benefit from radiation therapy in the long run.
Biomarker That Could Predict Survival After CRC Surgery Discovered
Research scientists at the Macquarie University and Concord Repatriation General Hospital in Australia have discovered that expression of the cell surface protein uPAR can predict survival after colorectal cancer (CRC) surgery. The study found that patients expressing uPAR may have undetectable cancer metastasis and dramatically poorer survival.
Minnesota’s McCullough to Serve as Guest Editor for AJMC’s 5th Annual Special Issue on Health IT
Jeffrey S. McCullough, PhD, who writes frequently on the intersection of health information technology (IT) and quality, will serve as guest editor for the 5th annual special issue of The American Journal of Managed Care
devoted to research and commentary on health IT. Dr McCullough’s services come during AJMC
’s celebration of its 20th year as the leading peer-reviewed journal covering healthcare delivery systems.
Balancing Value, Pathways, and Innovation in Healthcare
As specialty drug costs, formulary wars, and reimbursement models grab headlines everyday, we need to take a step back and visualize how all of this might impact innovation and whether the patient stands to lose in the process.
CVS Demands Cost Control for Novel Cholesterol Treatments
Two PCSK9 inhibitors under development—one by Amgen and the other jointly by Sanofi and Regeneron—could eventually cost the US healthcare system $150 billion per year. William Shrank, the chief scientific officer of CVS thinks these costs would be unsustainable for the healthcare industry that is already rattled by the burgeoning cost of specialty medications.
FDA Expands Indication for Revlimid in Multiple Myeloma
The combination of Revlimid with dexamethasone, previously approved for treatment in patients with multiple myeloma who received at least 1 prior treatment, has received FDA approval for use in newly diagnosed multiple myeloma patients.
Doctors Need to Be Tech Savvy, Report Suggests
The survey, conducted by salesforce.com, showed that 71% patients want their doctor to use a mobile application to schedule appointments, share health data, and manage preventive care; 60% patients reported an interest in using telehealth in place of in-person visits.